Schizophrenia Research
Volume 116, Issue 1 , Page 97 , January 2010

Treatment of co-morbid cocaine dependence in schizophrenia with topiramate

Received 11 September 2009 ,Revised 25 September 2009 ,Accepted 30 September 2009.

References 

  1. Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Subst. Abuse. 2008;29(3):51–63
  2. Green AI, et al. Schizophrenia and co-occurring substance use disorder. Am. J. Psychiatry. 2007;163:402–408
  3. Benes FM. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?. Biol. Psychiatry. 2009;65(12):1003–1005
  4. Cubells JF. Topiramate for cocaine dependence. Curr. Psychiatry Rep. 2006;8(2):130–131
  5. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641–1651
  6. Johnson BA, Ait-Daoud N, Akthar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers. Arch. Intern. Med. 2005;165:1600–1605
  7. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233–240

PII: S0920-9964(09)00484-8

doi: 10.1016/j.schres.2009.09.040

Schizophrenia Research
Volume 116, Issue 1 , Page 97 , January 2010

Article Tools